Choosing treatment for stage I seminoma: Who should get what?

Benjamin Garmezy, Lance C. Pagliaro

Research output: Contribution to journalComment/debate

3 Scopus citations

Abstract

We agree that physicians should choose active surveillance for their patients if they have the means to afford health insurance and are relatively stable within their careers. Prophylactic radiotherapy should be offered to patients who need a relaxed follow-up schedule for financial, emotional, or compliance reasons. For adjuvant carboplatin, longer follow-up data are needed to better define survival, long-term toxicities, frequency of second primary testicular cancers, quality of life, and cost to the health-care system.

Original languageEnglish (US)
JournalOncology
Volume23
Issue number9
StatePublished - Aug 2009

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Choosing treatment for stage I seminoma: Who should get what?'. Together they form a unique fingerprint.

  • Cite this

    Garmezy, B., & Pagliaro, L. C. (2009). Choosing treatment for stage I seminoma: Who should get what? Oncology, 23(9).